Pharmacytimes http://www.pharmacytimes.com/rss PharmacyTimes.com offers continuing education (CE) courses, career guidance for pharmacy students, online-only articles, digital versions of the print issue, and more, that are essential to pharmacists en-us Wed, 23 Jan 19 19:54:00 +0000 Wed, 23 Jan 19 19:54:00 +0000 Monday Pharmaceutical Mystery: January 21 http://www.pharmacytimes.com/news/monday-pharmaceutical-mystery-january-21 http://www.pharmacytimes.com/news/monday-pharmaceutical-mystery-january-21 Can you solve the pharmaceutical mystery?&nbsp; Mon, 21 Jan 19 15:00:00 +0000 FDA Announces Recall of Some Lots of Blood Pressure Medications http://www.pharmacytimes.com/news/fda-announces-recall-of-some-lots-of-blood-pressure-medications http://www.pharmacytimes.com/news/fda-announces-recall-of-some-lots-of-blood-pressure-medications One lot of irbesartan and 7 lots of irbesartan and hydrochlorothiazide (HCTZ) combination tablets distributed by Solco Healthcare, a Prinston Pharmaceutical subsidiary are affected. Fri, 18 Jan 19 22:33:00 +0000 Third Trastuzumab Biosimilar Granted FDA Approval http://www.pharmacytimes.com/news/third-trastuzumab-biosimilar-granted-fda-approval http://www.pharmacytimes.com/news/third-trastuzumab-biosimilar-granted-fda-approval Officials with the FDA have approved Samsung Bioepis&rsquo; Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin,&nbsp;for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer. Fri, 18 Jan 19 20:46:00 +0000 FDA Approves Generic Vigabatrin Treatment for Seizures http://www.pharmacytimes.com/news/fda-approves-generic-vigabatrin-treatment-for-seizures http://www.pharmacytimes.com/news/fda-approves-generic-vigabatrin-treatment-for-seizures Officials with the FDA today approved the first generic version of vigabatrin 500-mg tablets, which is also sold under the brand name Sabril, a medication used to treat complex partial seizures. Wed, 16 Jan 19 20:27:00 +0000 Walmart Leaves CVS Partnership Over Reimbursement http://www.pharmacytimes.com/news/walmart-leaves-cvs-partnership-over-reimbursement http://www.pharmacytimes.com/news/walmart-leaves-cvs-partnership-over-reimbursement CVS Caremark has requested that Walmart continue to fill prescriptions as an in-network participating pharmacy through&nbsp;April 30, 2019. Tue, 15 Jan 19 15:58:00 +0000 Personal Experience Made #ThankAPharmacist Contest Winner a Better Pharmacist http://www.pharmacytimes.com/news/personal-experience-made-thankapharmacist-contest-winner-a-better-pharmacist http://www.pharmacytimes.com/news/personal-experience-made-thankapharmacist-contest-winner-a-better-pharmacist Meet our #ThankAPharmacist Twitter contest winner, Dr. Lee Golden.&nbsp; Tue, 15 Jan 19 14:43:00 +0000 Cabozantinib Granted FDA Approval for Advanced HCC http://www.pharmacytimes.com/news/cabozantinib-granted-fda-approval-for-advanced-hcc http://www.pharmacytimes.com/news/cabozantinib-granted-fda-approval-for-advanced-hcc The FDA has approved cabozantinib (Cabometyx, Exelixis) as a treatment for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar, Bayer). Tue, 15 Jan 19 14:00:00 +0000 Pharmacists Are Happy With Their Salaries, Less So With Their Jobs, Survey Shows (Part 1) http://www.pharmacytimes.com/news/pharmacists-are-happy-with-their-salaries-less-so-with-their-jobs-survey-shows-part-1 http://www.pharmacytimes.com/news/pharmacists-are-happy-with-their-salaries-less-so-with-their-jobs-survey-shows-part-1 The <em>Pharmacy Times</em> Salary and Job Satisfaction Survey shows that workload, management, and work/life balance were the 3 top drivers of dissatisfaction. Sat, 12 Jan 19 13:00:00 +0000 National Pharmacist Day Elicits Pride for the Profession http://www.pharmacytimes.com/news/national-pharmacist-day-elicits-pride-for-the-profession http://www.pharmacytimes.com/news/national-pharmacist-day-elicits-pride-for-the-profession Tomorrow, pharmacists will be in the spotlight. It is also an opportunity for&nbsp;them to <a href="https://www.pharmacytimes.com/news/celebrating-the-role-of-pharmacists-in-health-care"><u>express pride in their work and share aspects of the job</u></a> that keep them motivated. Fri, 11 Jan 19 22:04:00 +0000 Midwestern University Announces Creation of Pharmacometrics Center http://www.pharmacytimes.com/news/midwestern-university-announces-creation-of-pharmacometrics-center http://www.pharmacytimes.com/news/midwestern-university-announces-creation-of-pharmacometrics-center In response to a growing demand for personalized medicine, the Midwestern University Chicago College of Pharmacy earlier this week announced the establishment of a Pharmacometrics Center of Excellence on the school&rsquo;s Downers Grove Campus. Fri, 11 Jan 19 18:39:00 +0000 Celebrating the Role of Pharmacists in Health Care http://www.pharmacytimes.com/news/celebrating-the-role-of-pharmacists-in-health-care http://www.pharmacytimes.com/news/celebrating-the-role-of-pharmacists-in-health-care On National Pharmacist Day, share your #APharmacistIs story on social media. Thu, 10 Jan 19 21:00:00 +0000 Treatment App Available by Prescription for Adults With Opioid Use Disorder http://www.pharmacytimes.com/news/treatment-app-available-by-prescription-for-adults-with-opioid-use-disorder- http://www.pharmacytimes.com/news/treatment-app-available-by-prescription-for-adults-with-opioid-use-disorder- An FDA-approved mobile application for adults with opioid use disorder (OUD) is now available by prescription.&nbsp;Pear Therapeutics&rsquo; reSET-O app aims to increase retention for adults who are in outpatient treatment programs. Wed, 09 Jan 19 17:00:00 +0000 Vecuronium Bromide Powder Recalled Nationwide http://www.pharmacytimes.com/news/vecuronium-bromide-powder-recalled-nationwide http://www.pharmacytimes.com/news/vecuronium-bromide-powder-recalled-nationwide Sun Pharmaceutical Industries, Inc. (SPI) is voluntarily recalling 3 lots of 10 mg vecuronium bromide for injection and 1 lot of 20 mg vecuronium bromide for injection to the hospital level. Tue, 08 Jan 19 21:00:00 +0000 Breakthrough Therapy Designation Granted for Sickle Cell Disease Treatment http://www.pharmacytimes.com/news/breakthrough-therapy-designation-granted-for-sickle-cell-disease-treatment http://www.pharmacytimes.com/news/breakthrough-therapy-designation-granted-for-sickle-cell-disease-treatment Officials with the FDA have granted Breakthrough Therapy designation to Novartis&rsquo; crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease. Tue, 08 Jan 19 18:00:00 +0000 Lupin Recalls 42 Lots of Ceftriaxone for Injection http://www.pharmacytimes.com/news/lupin-recalls-42-lots-of-ceftriaxone-for-injection http://www.pharmacytimes.com/news/lupin-recalls-42-lots-of-ceftriaxone-for-injection Lupin Pharmaceuticals, Inc. has voluntarily recalled 42 of lots of Ceftriaxone for Injection, USP products at the hospital/physician level. These products were found to contain visual grey particulate matter in reconstituted vials. Mon, 07 Jan 19 13:00:00 +0000 Dasatinib Approved for Treatment of Certain Pediatric Patients http://www.pharmacytimes.com/news/dasatinib-approved-for-treatment-of-certain-pediatric-patients- http://www.pharmacytimes.com/news/dasatinib-approved-for-treatment-of-certain-pediatric-patients- The FDA has approved dasatinib (Sprycel, Briston-Myers Squibb) tablets in combination with chemotherapy for the treatment of pediatric patients &ge;1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Wed, 02 Jan 19 22:48:00 +0000 Study: Genetic Risk Variant Linked to Astrocytes Increases Risk of MS http://www.pharmacytimes.com/news/study-genetic-risk-variant-linked-to-astrocytes-increases-risk-of-ms http://www.pharmacytimes.com/news/study-genetic-risk-variant-linked-to-astrocytes-increases-risk-of-ms Study results show a&nbsp;genetic risk variant on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis. Wed, 02 Jan 19 14:00:00 +0000 Top Read Articles of the Year http://www.pharmacytimes.com/news/top-read-articles-of-the-year http://www.pharmacytimes.com/news/top-read-articles-of-the-year We analyzed the data, and these are the articles our audience was most interested in reading online this year.&nbsp; Wed, 26 Dec 18 16:08:00 +0000 CDC: Drug Overdoses Linked to Synthetic Opioids Rose in Recent Years http://www.pharmacytimes.com/news/cdc-drug-overdoses-linked-to-synthetic-opioids-rose-in-recent-years http://www.pharmacytimes.com/news/cdc-drug-overdoses-linked-to-synthetic-opioids-rose-in-recent-years Opioids were involved in over two-thirds of overdose deaths in 2017.&nbsp; Wed, 26 Dec 18 13:36:00 +0000 Drug for Treating Rare, Aggressive Cancer Receives FDA Approval http://www.pharmacytimes.com/news/drug-for-treating-rare-aggressive-cancer-receives-fda-approval http://www.pharmacytimes.com/news/drug-for-treating-rare-aggressive-cancer-receives-fda-approval The FDA has approved tagraxofusp-erzs (Elzonris,&nbsp;Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older. Fri, 21 Dec 18 17:48:00 +0000 New Treatment Granted FDA Approval for Adults With Rare Blood Disease PNH http://www.pharmacytimes.com/news/new-treatment-granted-fda-approval-for-adults-with-rare-blood-disease-pnh http://www.pharmacytimes.com/news/new-treatment-granted-fda-approval-for-adults-with-rare-blood-disease-pnh Ravulizumab (Ultomiris, Alexion) is the first long-acting complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinura. Fri, 21 Dec 18 17:00:00 +0000 Cigna Completes Purchase of Express Scripts http://www.pharmacytimes.com/news/cigna-completes-purchase-of-express-scripts http://www.pharmacytimes.com/news/cigna-completes-purchase-of-express-scripts Cigna recently announced the completion of its $54-billion acquisition of Express Scripts. Fri, 21 Dec 18 15:45:00 +0000 FDA Approves Calaspargase Pegol-mknl for Young Patients With ALL http://www.pharmacytimes.com/news/fda-approves-calaspargase-pegolmknl-for-young-patients-with-all http://www.pharmacytimes.com/news/fda-approves-calaspargase-pegolmknl-for-young-patients-with-all The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients Fri, 21 Dec 18 13:00:00 +0000 Pharmacist Organization Formed to Increase Access to Care for Hispanic Communities http://www.pharmacytimes.com/news/pharmacist-organization-formed-to-increase-access-to-care-for-hispanic-communities http://www.pharmacytimes.com/news/pharmacist-organization-formed-to-increase-access-to-care-for-hispanic-communities The&nbsp;National Hispanic Pharmacists Association was launched by the&nbsp;National Hispanic Health Foundation with public and private sector partners.&nbsp; Thu, 20 Dec 18 16:00:00 +0000 Pembrolizumab Gains FDA Approval for Merkel Cell Carcinoma http://www.pharmacytimes.com/news/pembrolizumab-gains-fda-approval-for-merkel-cell-carcinoma http://www.pharmacytimes.com/news/pembrolizumab-gains-fda-approval-for-merkel-cell-carcinoma The FDA granted an accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients&nbsp;with recurrent locally advanced or metastatic Merkel cell carcinoma. Wed, 19 Dec 18 20:32:00 +0000